BioNTech Reports Promising Phase 2 Results for mRNA Immunotherapy BNT111 in Advanced Melanoma Patients
BioNTech Announces Promising Phase 2 Results for mRNA Immunotherapy BNT111 in Advanced Melanoma BioNTech today revealed positive topline data from its ongoing Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899)…
WuXi AppTec Reports Stable Operations and Growth in Q2 2024: Revenue Up 16% QoQ, Adjusted Net Profit Up 28.5% QoQ
WuXi AppTec Reports First Half 2024 Financial Results WuXi AppTec, a global leader in R&D and manufacturing services for the pharmaceutical and life sciences sectors, has announced its financial results…
New Data: 3 Years of LEQEMBI® Treatment Benefits Early Alzheimer’s Patients
Today, Eisai Co. Ltd. presented new findings on lecanemab-irmb (branded as LEQEMBI® in the U.S.) at the Alzheimer’s Association International Conference (AAIC) 2024 in Philadelphia and online. This dual-acting anti-amyloid…
Biogen, Beckman Coulter, and Fujirebio Collaborate on Blood Test for Alzheimer’s Tau Pathology
Biogen, Beckman Coulter, and Fujirebio have announced a collaboration to identify and develop blood-based biomarkers for tau pathology in Alzheimer’s disease (AD). The goal is to create new tests that…
Vertex Announces FDA Acceptance of Suzetrigine NDA for Acute Pain
Vertex Announces FDA Acceptance of Suzetrigine NDA for Acute Pain Vertex Pharmaceuticals today revealed that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for…
AMPLIFY Phase III Trial: Fixed-Duration Calquence and Venetoclax, ± Obinutuzumab, Boosts PFS in 1st-Line CLL
The interim analysis of the AMPLIFY Phase III trial revealed promising results for AstraZeneca’s Calquence (acalabrutinib) combined with venetoclax, with or without obinutuzumab, in treating chronic lymphocytic leukaemia (CLL). The…
FDA Grants Priority Review to Novartis’ Scemblix® for Newly Diagnosed CML
Novartis announced that the US Food and Drug Administration (FDA) has granted Priority Review status to Scemblix® (asciminib) for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic…
Allergan Aesthetics Celebrates Second Annual JUVÉDERM® Day
Allergan Aesthetics is excited to announce the return of JUVÉDERM® Day on Wednesday, August 21. Following the success of its inaugural event, JUVÉDERM® Day offers limited-time deals, savings, and exclusive…
European Commission Approves Roche’s Vabysmo for Retinal Vein Occlusion (RVO) Treatment
The European Commission (EC) has approved Vabysmo® (faricimab) for treating visual impairment caused by macular edema secondary to retinal vein occlusion (RVO), which includes branch RVO and central RVO. This…
Roche Acquires LumiraDx’s Point-of-Care Tech to Boost Primary Care Diagnostics
Roche announced today the completion of its acquisition of LumiraDx’s Point-of-Care technology, following the necessary antitrust and regulatory approvals. The acquisition will see Roche integrate LumiraDx’s multi-assay point-of-care platform, along…
AbbVie Announces Financial Results for Q2 2024
AbbVie Reports Strong Second-Quarter 2024 Financial Performance AbbVie has announced its financial results for the second quarter ending June 30, 2024. “Our business continues to excel, with second-quarter outcomes significantly…
AbbVie Gains EU Approval for SKYRIZI® to Treat Ulcerative Colitis
AbbVie Announces European Approval of SKYRIZI® for Ulcerative Colitis AbbVie has received European Commission approval for SKYRIZI® (risankizumab) to treat adults with moderately to severely active ulcerative colitis (UC) who…